

RESEARCH

Open Access

Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis

Paul E Polak¹, Randall O Dull¹, Sergey Kalinin¹, Anthony J Sharp², Richard Ripper², Guy Weinberg^{1,2}, David E Schwartz¹, Israel Rubinstein^{2,3} and Douglas L Feinstein^{1,2*}

Abstract

Background: Inhalational anesthetics have been shown to influence T cell functions both *in vitro* and *in vivo*, in many cases inducing T cell death, suggesting that exposure to these drugs could modify the course of an autoimmune disease. We tested the hypothesis that in mice immunized to develop experimental autoimmune encephalomyelitis (EAE), a well established model of multiple sclerosis (MS), treatment with the commonly used inhalational anesthetic sevoflurane would attenuate disease symptoms.

Methods: C57Bl6 female mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide residues 35 to 55 to induce a chronic demyelinating disease. At day 10 after immunization, the mice were subjected to 2 h of 2.5% sevoflurane in 100% oxygen, or 100% oxygen, alone. Following treatment, clinical scores were monitored up to 4 weeks, after which brain histology was performed to measure the effects on astrocyte activation and lymphocyte infiltration. Effects of sevoflurane on T cell activation were studied using splenic T cells isolated from MOG peptide-immunized mice, restimulated *ex vivo* with MOG peptide or with antibodies to CD3 and CD28, and in the presence of different concentrations of sevoflurane. T cell responses were assessed 1 day later by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for proliferation, lactate dehydrogenase (LDH) release for cell death, and inflammatory activation by production of interleukin (IL)-17 and interferon (IFN) γ .

Results: Clinical scores in the oxygen-treated group increased until day 28 at which time they showed moderate to severe disease (average clinical score of 2.9). In contrast, disease progression in the sevoflurane-treated group increased to 2.1 at day 25, after which it remained unchanged until the end of the study. Immunohistochemical analysis revealed reduced numbers of infiltrating leukocytes and CD4⁺ cells in the CNS of the sevoflurane-treated mice, as well as reduced glial cell activation. In splenic T cells, low doses of sevoflurane reduced IFN γ production, cell proliferation, and increased LDH release.

Conclusions: These results are the first to show attenuation of EAE disease by an inhaled anesthetic and are consistent with previous reports that inhaled anesthetics, including sevoflurane, can suppress T cell activation that, in the context of autoimmune diseases such as MS, could lead to reduced clinical progression.

Keywords: Myelin, Experimental autoimmune encephalomyelitis, Inhaled anesthetic, Multiple sclerosis

* Correspondence: dlfeins@uic.edu

¹Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA

²Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA

Full list of author information is available at the end of the article

Background

Accumulating data suggests that inhaled anesthetics (IAs; this includes sevoflurane, isoflurane, and desflurane) can exacerbate inflammation and lead to neuronal damage in older patients and patients suffering from Alzheimer's disease (AD). As an example, sevoflurane increased caspase activation and apoptosis, altered amyloid precursor protein (APP) processing, and increased β -amyloid levels in the brains of transgenic mouse models of AD [1] and in APP-expressing cells [1,2]. These studies were based on observations that small molecular weight hydrophobic alkanes can shift oligomerization of proteins such as β -amyloid towards higher oligomers and increase cytotoxicity [3-5]. However, it has been known for many years that certain IAs modulate inflammatory responses in peripheral cells and tissues; although usually associated with suppression of cell activation, in some cases IAs increase inflammatory responses [6].

Multiple sclerosis (MS) is an autoimmune disease that affects approximately 400,000 people in the US and over 2 million people worldwide. The exact causes of MS are not yet precisely known, however, it is well established that activation of the adaptive immune system leads to activation and proliferation of T cells that can infiltrate the central nervous system and release cytokines that lead to oligodendrocyte damage, demyelination, and axonal damage. The infiltrating cells also induce inflammatory activation of resident glial cells, including astrocytes and microglia, which can propagate and maintain disease pathology. Several treatments which reduce T cell activation, proliferation, infiltration into the CNS, or cytokine production are currently used to reduce MS symptoms; however, additional non-invasive, safe methods to modulate T cell functions still have potential value for MS treatment.

In this regard, IAs have been shown to exert significant effects on T cells [7-13], influencing their adhesion properties [14,15] and modifying their inflammatory responses [12,16-19]. It is thought that regional anesthesia can improve postoperative recovery by reducing immunosuppression [20]. For example, in normal adult male mice, 40 minutes with sevoflurane increased the total number of CD4⁺ lymphocytes in the spleen [12]; and *in vitro* sevoflurane increased P-selectin expression and platelet:leukocyte adherence in whole blood [14]; and induced activation of several signaling factors (apoptosis signal-regulating kinase 1 (ASK1), mitogen-activated protein kinase kinase (MAPKK)3 and 6; activating transcription factor 2 (ATF2), and p38 MAPK) in human Jurkat cells [21]. There are also reports that IAs reduce T cell activation or activity; for example both sevoflurane and isoflurane induced apoptosis in whole peripheral blood mononuclear cells (PBMCs) [11]; and

desflurane reduced cell adhesion molecule expression in human endothelial cells [22].

These above findings suggest that administration of IAs could impact the course of an autoimmune disease such as MS. However, the possible effects of IAs on the progression of MS symptoms or pathology have not been characterized. A few case reports suggest that sevoflurane does not worsen immediate postoperative recovery [23-25]; however, there are no publications testing either acute or delayed effects of IAs in animal models of MS. In view of the above findings we hypothesized that IA exposure would influence the clinical course of disease in experimental autoimmune encephalomyelitis (EAE), a well characterized model of MS. Our findings indicate that sevoflurane attenuates the progression of clinical disease in EAE mice, which may be due to suppression of T cell activation.

Methods

Materials

General chemicals and reagents were from Sigma (St Louis, MO, USA). Secondary antibodies were from Vector Labs (Burlingame, CA, USA). Myelin oligodendrocyte glycoprotein peptide residues 35 to 55 (MOG₃₅₋₅₅; MEVGWYRSPFSRVVHLYRNGK) was purchased from Anaspec (San Jose, CA, USA).

Mice

Female C57BL/6 mice aged 6 to 8 weeks were purchased from Charles River Breeding (Cambridge, MA, USA). Mice were housed five per cage, and kept in a controlled 12 h light/12 h dark environment and provided food *ad libitum*. All animal procedures were approved by the local Institutional Animal Care and Use Committee (IACUC) committee.

Induction of EAE

EAE was actively induced in using synthetic MOG₃₅₋₅₅ as described previously [26]. Mice were injected subcutaneously (two 100 μ l injections into adjacent areas in one hind limb) with an emulsion of 300 μ g MOG₃₅₋₅₅ dissolved in 100 μ l phosphate-buffered saline (PBS), mixed with 100 μ l complete Freund's adjuvant containing 500 μ g of *Mycobacterium tuberculosis* (Difco, Detroit, MI, USA). Immediately after MOG₃₅₋₅₅ injection, the animals received an intraperitoneal injection of pertussis toxin (PT; 200 ng in 200 μ l PBS). Then, 2 days later the mice received a second PT injection, and 1 week later they received a booster injection of MOG₃₅₋₅₅. This protocol leads to an incidence of >90%, low mortality, average clinical signs between three and four (one or two hindlimbs with paresis or paralysis), lasting disease with no recovery for up to 3 months; frank demyelination in the spinal cords and cerebellum; and neuronal damage

by 2 months. Clinical signs were scored on a five-point scale: grade 0, no clinical signs; 1, limp tail; 2, impaired righting; 3, paresis of one hind limb; 4, paresis of two hind limbs; 5, death. When a mouse died it was assigned a score of 5, and that score was carried through for the rest of the study for statistical analysis. Scoring was performed at the same time each day by an investigator blinded to allocation.

Treatment with sevoflurane

At 10 days after the booster immunization, at which point mice begin to show clinical signs, mice were subjected to 2 h 2.5% sevoflurane in 100% oxygen, or as control to 2 h of 100% oxygen. Anesthetics and oxygen were provided to mice as a group in a glass chamber. The gas pressure was continuously monitored. After 2 h, the mice were allowed to recover and returned to home cages and monitored for a further 4 weeks. At the end of the study the mice were killed to prepare brain sections for histology and immunocytochemical staining.

Tissue preparation and immunohistochemistry

Mouse brains were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.6 overnight at 4°C. Dehydration, embedding, paraffin removal, and sectioning were performed using standard protocols as described [27]. Serial sagittal sections (8 µm) were obtained by starting from the midline and included the cerebellum. Following paraffin removal, antigen retrieval was accomplished by boiling in 10 mM citrate buffer for 10 minutes, then blocking with 5% normal donkey serum. Sections were incubated at 4°C overnight with primary antibodies diluted in 1% normal donkey serum: rat monoclonal anti-human glial fibrillary acidic protein (GFAP) B2.210 at 1:300 [28]. After washing, sections were incubated 1 h at 37°C with donkey anti-rabbit rhodamine red-X (RRX) conjugated or donkey anti-rat conjugated with fluorescein isothiocyanate (FITC) secondary antibodies. Sections were washed, fixed with 3.7% formaldehyde in phosphate buffered saline (PBS), quenched in 50 mM ammonium chloride in PBS for 15 minutes, then final washes performed in PBS with 400 ng/ml 4',6-diamidino-2-phenylindole (DAPI) included in the second wash. Vectashield mounting fluid (Vector Laboratories Inc.) was placed onto sections prior to coverslips placed.

Infiltrating cells

Histological examination for infiltrating cells was performed by staining deparaffinized, washed sections with hematoxylin and eosin (H&E). Serial sections through the cerebellum of each mouse were examined for infiltrates and the number of large (>5,000 µm²) or small (<5,000 µm²) areas of infiltration counted.

Image analysis

Images were obtained on a Zeiss Axioplan 2 microscope using an MRm Axiocam for image acquisition and densitometric analysis conducted using Axiovision version 4.5 software (Carl Zeiss Inc. Thornwood, NY, USA). Image acquisition was conducted on sections stained simultaneously and exposed for identical amounts of time. Quantitation of GFAP staining was performed using an object area cutoff of 10 µm² to include cell bodies and processes. The data were analyzed to determine the total area covered by positively stained objects presented as a percentage of the total field of view.

Splenic T cell isolation and analyses

Splenocytes were isolated from mice 10 days after the booster MOG immunization. After lysis of red blood cells, splenocytes were plated into 24 well plates at a density of 2×10^5 cells per well in 400 µl RPMI media containing 10% fetal calf serum. The cells were restimulated with MOG₃₅₋₅₅ peptide (20 µg/ml), or the T cell receptor (TCR) directly activated with rat monoclonal anti-CD3 (0.20 µg/ml) and anti-CD28 (0.5 µg/ml) antibodies. Cells were incubated with indicated concentrations of sevoflurane or equivalent amount of vehicle. After 1 day, aliquots of the media were assayed for levels of interleukin (IL)-17 and interferon (IFN)γ by ELISA following the manufacturer's instructions (eBioscience, San Diego, CA, USA). Cell proliferation was assessed indirectly using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to measure mitochondrial content; and cell viability after 24 h by measurement of lactate dehydrogenase (LDH) released into the media (Promega, Madison, WI, USA).

Data analysis

Comparison of clinical signs over time in one group was performed via one-way, non-parametric analysis of variance (ANOVA) (Kruskal-Wallis test) followed by Dunn's multiple comparison tests. Comparison of the effect of treatment versus control on the development of clinical signs was performed via two-way repeated measures ANOVA. Two group comparisons were performed by Mann-Whitney non-parametric unpaired t tests. Effects of sevoflurane on T cell parameters were compared by parametric one-way ANOVA followed by Tukey *post hoc* comparisons. In all cases significance was taken at $P < 0.05$.

Results

Sevoflurane attenuates development of clinical signs of EAE

C57Bl6 mice were immunized with MOG₃₅₋₅₅ peptide to develop a chronic demyelinating disease using a standardized protocol. At day 10 after the booster immunization,

at which point the mice were just beginning to show clinical signs, they were treated for 2 h with 2.5% sevoflurane dissolved in 100% oxygen, or with 100% oxygen alone. Clinical scores were then monitored for the next 4 weeks. In both groups the incidence of diseases reached 100% at day 23 (Figure 1A). In the control group, clinical scores increased over time (Figure 1B) reaching a maximum value of 2.86 ± 0.46 at day 28; during this time one mouse died at day 25. In the sevoflurane-treated group, clinical scores increased similarly to the control group up until day 25, at which point the scores remained stable until the end of the study (2.14 ± 0.15). The difference in clinical score development in the sevoflurane-treated mice was statistically different than the control mice ($F[9,1] = 1.98$, $P = 0.049$, two-way repeated measures ANOVA).

Sevoflurane reduces leukocyte infiltration

At the end of the studies described above, serial sagittal sections were prepared from brains of the oxygen-treated and sevoflurane-treated mice for histological and immunocytochemical analysis. H&E staining to visualize infiltrating cells (Figure 2) showed that while leukocyte infiltration could be detected in the cerebellum of both oxygen-treated and sevoflurane-treated mice, there was a trend to fewer total number of areas of infiltrates in the sevoflurane-treated mice. Classification into larger ($>5,000 \mu\text{m}^2$) and smaller ($<5,000 \mu\text{m}^2$) areas of infiltrates (Figure 2C) shows that sevoflurane significantly

reduced the number of smaller regions containing infiltrating cells.

Immunostaining using an antibody to the T cell receptor CD4 (Figure 3) revealed the presence of small CD4⁺ stained cells throughout the brain and large numbers in the white matter of the cerebellum of the oxygen-treated mice. In sevoflurane-treated mice, the number of CD4⁺ stained cells in this area of the cerebellum was reduced by 50% ($P < 0.05$).

Sevoflurane reduces glial activation in EAE

During EAE, the production of inflammatory mediators from infiltrating T cells leads to the activation of parenchymal glial cells (astrocytes and microglia) throughout the brain and spinal cord. A reduction in T cell numbers could therefore reduce overall glial activation. To test this, we stained serial sections through the cerebellum for the astrocyte specific marker GFAP (Figure 4). In sections from oxygen-treated mice, we observed strong GFAP staining throughout the cerebellum in both the white matter and in the Bergmann radial glial cells (Figure 4A). In the sevoflurane samples (Figure 4B), GFAP staining in the white matter was much less, and only minimal staining of Bergmann glial was observed. Quantitative image analysis confirmed that total GFAP staining in the cerebellum was significantly reduced by 30% in the sevoflurane-treated mice compared to controls (Figure 4C).





Figure 1 Sevoflurane attenuates development of clinical scores in experimental autoimmune encephalomyelitis (EAE). Female C57Bl/6 mice were immunized with myelin oligodendrocyte glycoprotein (MOG)₃₅₋₅₅ peptide to develop EAE as described in the Methods section. At 10 days after the MOG booster, the mice were subjected to 2 h of 2.5% sevoflurane in 100% oxygen (open circles), or 100% oxygen alone (filled circles). Clinical scores were monitored for the next 4 weeks. **(A)** Daily incidence of disease over the course of the study for both groups. **(B)** Mean \pm SEM of average clinical scores of one experiment performed with $n = 7$ mice per group; similar results were obtained in a second independent study. $F[9,1] = 1.98$, $P = 0.049$, two-way repeated measures analysis of variance (ANOVA).




Sevoflurane reduces T cell activation *in vitro*



Reduced leukocyte infiltration into the CNS could be due, in part, to suppression of T cell activation by sevoflurane. To test this possibility, splenic T cells were isolated from MOG-immunized mice and activated *in vitro* with MOG peptide or with antibodies to the TCR CD3 and costimulatory receptor CD28 (Figure 5). After 24 h, the T cells produced significant amounts of proinflammatory cytokines IFN γ (Figure 5A) and IL-17 (Figure 5B) compared to non-activated cells, and those levels were greater in the TCR activated cells. In MOG-treated cells, IFN γ levels were reduced by low doses of sevoflurane (0.20 to 1.0 mM); in CD3/28-treated cells only 1.0 mM sevoflurane showed a significant reduction. Sevoflurane at these doses did not significantly reduce IL-17 levels in the media.

Assessment of mitochondrial content using the MTT assay showed a significant increase in cell proliferation due to MOG or to CD3/28 as compared to non-treated cells (Figure 6A). In MOG-treated cells, proliferation was reduced by 1.0 mM sevoflurane, whereas in the CD3/28-treated cells both 0.5 and 1.0 mM sevoflurane reduced proliferation. Measurements of LDH release showed that sevoflurane at 0.5 and 1.0 mM significantly increased cell death in both MOG-treated and CD3/28-treated cells, but not in vehicle-treated cells.

Discussion

To the best of our knowledge this is the first study to demonstrate neuroprotective effects due to sevoflurane inhalation that attenuated the development of clinical symptoms in experimental autoimmune encephalitis, a








Figure 6 Sevoflurane reduces T cell proliferation and induces T cell death. Splenic T cells as described in Figure 5 were assayed after 24 h for (A) cell proliferation using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; and (B) cell death by measurement of lactate dehydrogenase (LDH) in the culture media. The data are mean \pm SEM of $n = 4$ samples per group, and are relative to values measured for vehicle-treated cells with 0 sevoflurane. $^{\&}P < 0.05$ versus vehicle, 0 sevoflurane (t test); $*P < 0.05$ versus 0 sevoflurane (one way analysis of variance (ANOVA), Tukey *post hoc* test).

well established model of multiple sclerosis. A single exposure of mice to 2.5% sevoflurane for 2 h arrested the continuing development of neurological symptoms related to EAE. This functional neurological protection was associated with a reduction of inflammatory cells within the brain and reduced levels of glial cell activation. In parallel, *in vitro* studies showed inhibitory actions of low doses (between 0.20 and 1.0 mM) sevoflurane on T cell activation, as indicated by reduced accumulation of IFN γ in the culture media, reduced cell proliferation, and increased cell death. These results suggest that low doses of sevoflurane may provide benefit in EAE by suppression of T cell responses.

To place these studies and methodology in a clinical context, patients typically receive sevoflurane, which has a minimum alveolar concentration (MAC) = 1.89, in the range of 1.5% to 2.5%. Measurements of blood levels from patients receiving sevoflurane at 1.5% demonstrated concentrations ranging from 43 to 58 $\mu\text{g/ml}$ or approximately 0.25 mM [29]. Therefore, in our whole animal studies and the *in vitro* studies, concentrations of sevoflurane of 2.5% and 0.5 mM, respectively, are within the clinically relevant range during general anesthesia.

EAE induced by MOG peptide typically results in onset of clinical symptoms beginning at about day

10 after the booster immunization, with a progressive worsening that plateaus near day 25. In this study, the control, oxygen-treated EAE mice reached a maximal clinical score of 2.86 ± 0.46 on day 28 after the booster MOG peptide immunization, which reflects modest to severe neurological injury. In contrast, clinical scores in the sevoflurane-treated mice plateaued at 2.29 ± 0.15 on day 23 after immunization, after which there was no further worsening. These findings suggest that a single exposure to sevoflurane at an early timepoint during the development of EAE can attenuate the ultimate magnitude of neurological damage, although it is not sufficient to reverse the initial damage that has already occurred. Whether longer exposure times, or multiple short exposures to sevoflurane can induce clinical recovery is currently under investigation.

Histological evaluation revealed significant reductions in lymphocytic infiltrates within the cerebellum in the sevoflurane-treated mice. When characterized as to either large ($>5,000 \mu\text{m}^2$) or small ($<5,000 \mu\text{m}^2$) areas of infiltration, the sevoflurane-treated animals showed a significant reduction in the number of smaller infiltrates. The pathophysiological significance of infiltrate size is not entirely clear but may be due to gradual enlargement of the earlier forming lesion sites. This suggests that sevoflurane is unable to prevent the enlargement

of pre-existing sites of infiltrates; but is able to attenuate development of new, smaller lesions.

Our *in vitro* studies point to suppressive actions of sevoflurane on T cells isolated from MOG peptide-immunized mice. This is consistent with previous studies which have described induction of apoptosis, or cell damaging effects of sevoflurane on T cells or lymphocytes, at similar or higher doses, or after longer time-points. For example, in CD3⁺ T cells, exposure to 8% sevoflurane, which resulted in a cell culture media concentration of 1.17 mM, induced significant cell apoptosis [10,21]. However exposure to lower doses (2.5%, or approximately 0.40 mM) did not induce apoptosis. In normal peripheral lymphocytes [11] after incubation with sevoflurane at concentrations of 0.5, 1.0, and 1.5 mM it was found that the lowest dose did not increase markers of apoptosis. Cell damaging effects at higher doses of sevoflurane have been reported in other lymphocytes, for example in human B cells, 10 mM sevoflurane (added as 20 μ l of the stock 7.5 M sevoflurane into 15.5 ml of saline) induced significant alterations in heme biosynthesis [7]. Our results show that a very low dose (0.20 mM) of sevoflurane could significantly reduce the production of the T helper 1 (Th1) cytokine IFN γ , but that up to 1.0 mM sevoflurane did not reduce IL-17. This suggests that sevoflurane differentially affects distinct T cell subtypes since these two cytokines are produced by Th1 and Th17 T cells, respectively. Further studies using enriched cell populations will be needed to address this possibility.

The ability of sevoflurane to induce T cell apoptosis or modify T cell functionality has been reported several times. As soon as 1 or 2 h after administration of sevoflurane (between 1% to 1.5% in oxygen:air mixture) there was an increase in DNA damage in blood lymphocytes [9]; *in vitro* exposure of normal human PBMCs to sevoflurane (0.5, 1.0, or 1.5 mM) induced apoptosis as soon as 6 h after exposure [11]. Similarly, exposure of healthy adult mice to 3% sevoflurane (1.2 MAC) for 40 minutes reduced the number of circulating PBMCs and splenic B cells, but increased CD4⁺ lymphocytes in the spleen when measured after 3 days [12], which persisted up to 9 days after anesthesia exposure [16]. The mechanisms by which sevoflurane induces lymphocyte damage are not clear. However, *in vitro* studies using human CD3 T cells showed that sevoflurane suppressed activation of transcription factor AP-1, which plays a role in T cell inflammatory activation [18] as well as inducing apoptosis [10]. These effects also involve protein kinase cascades including activation of the p38 kinase [21]. Interestingly, many of these effects were not observed following exposure to desflurane. In addition to inducing apoptosis, sevoflurane, as well as other inhalation anesthetics, can influence interactions of lymphocytes

with other cell types. For example, sevoflurane increased binding of platelets to lymphocytes, and increased expression of P-selectin on the platelets [14]. Sevoflurane inhibited binding of integrin lymphocyte function associated antigen 1 (LFA-1) to its ligand (intercellular adhesion molecule 1 (ICAM-1)) thereby accounting for its ability to reduce inflammatory activation through the ICAM-1 signaling pathway [15]. Whether some or all of these actions of sevoflurane contribute to the beneficial effects observed in the current study are not known; however reductions in numbers, inflammatory state, or migration of T cells (and B cells) would all be expected to be of benefit to diseases such as MS.

Collectively, the results presented in this study suggest that sevoflurane provides protection against T cell mediated neurological inflammation and the subsequent neurological sequelae resulting from T cell infiltration into the CNS and associated activation of parenchymal glial cells. Our immunochemical staining of the cerebellum was limited to CD4⁺ cells, we cannot rule out that the beneficial effects of sevoflurane are also due in part to reduced infiltration of other cell types such as macrophages or B cells. Measurements of direct effects of sevoflurane on neuronal integrity and axonal damage was beyond the scope of this investigation, but the positive functional protection raises intriguing possibilities for the use of inhaled anesthetic agents in the treatment of neuroinflammatory conditions. These conditions need not be confined solely to primary CNS diseases but viewed in a more global context of inflammation, such as sepsis, that results in wide spread inflammation including in the brain [30-32].

There has been significant interest in the effects of inhalational anesthetics on neuronal function (for example, anesthesia conditioning and protection) but also concern due to increased neuronal apoptosis following exposure to inhaled anesthetics. Widespread concern regarding the effects of inhalational anesthetics on the developing brain was the impetus for the SMARTTots (Strategies for Mitigating Anesthesia-Related neuroToxicity in Tots) program (formerly called SAFEKIDS), and US Food and Drug Administration (FDA)-driven panels to investigate potential long term sequelae of anesthesia in pediatric patients [33]. The concern regarding long term outcomes following exposure to inhalational agents arose on the heels of significant excitement related to widespread demonstration of protective effects of anesthesia preconditioning and even anesthesia post-conditioning in a variety of models including stroke, myocardial infarction and ischemia reperfusion injury. Unraveling the protective effects from injurious effects has proved to be challenging. In a recent review [34], it is apparent that the effects of inhalational anesthetics on the brain are complex and multifactorial and are

dependent upon subject age, comorbidities, duration of exposure, concentration and specific anesthetic agent. Collectively, it appears that higher concentrations and longer durations of exposure may be associated with increased neuronal cell death while lower concentrations may confer neuroprotection.

Conclusions

The current findings demonstrate that a single exposure to the inhaled anesthetic sevoflurane attenuates the progression of EAE, associated with reductions in glial cell activation and T cell infiltration. This raises the possibility that patients with autoimmune-based neurological diseases such as MS could also benefit from a similar treatment.

Abbreviations

AD: Alzheimer's disease; ANOVA: analysis of variance; APP: amyloid precursor protein; ASK1: apoptosis signal-regulating kinase 1; ATF2: activating transcription factor 2; CNS: central nervous system; DAPI: 4',6-diamidino-2-phenylindole; EAE: experimental autoimmune encephalomyelitis; FITC: fluorescein isothiocyanate; GFAP: glial fibrillary acidic protein; IA: inhaled anesthetic; IACUC: Institutional Animal Care and Use Committee; IL-17: interleukin-17; IFN γ : interferon γ ; LDH: lactate dehydrogenase; MAC: mean alveolar concentration; MAPKK: mitogen-activated protein kinase kinase; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBMC: peripheral blood mononuclear cells; PBS: phosphate-buffered saline; PT: pertussis toxin; RRX: rhodamine red-X; TCR: T cell receptor; Th1: T helper 1; Th17: T helper 17.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PEP carried out immunostaining for T cells and ELISAs; ROD helped draft the manuscript and discussed the clinical relevance; SK carried out immunostaining for glial cells; AJS immunized and scored mice; RR carried out sevoflurane exposure; GW supervised use of sevoflurane and helped draft the manuscript; DES help conceive of the original study plan; IR contributed to design of the study; DLF conceived the study, carried out data analysis, and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was funded in part by grants from the National Multiple Sclerosis Society (DLF) and the Department of Veterans Affairs (DLF, GW).

Author details

¹Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA.

²Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA.

³Department of Medicine, University of Illinois, Chicago, IL 60612, USA.

Received: 26 September 2012 Accepted: 26 November 2012

Published: 19 December 2012

References

1. Lu Y, Wu X, Dong Y, Xu Z, Zhang Y, Xie Z: **Anesthetic sevoflurane causes neurotoxicity differently in neonatal naive and Alzheimer disease transgenic mice.** *Anesthesiology* 2010, **112**:1404–1416.
2. Perucho J, Rubio I, Casarejos MJ, Gomez A, Rodriguez-Navarro JA, Solano RM, De Yébenes JG, Mena MA: **Anesthesia with isoflurane increases amyloid pathology in mice models of Alzheimer's disease.** *J Alzheimers Dis* 2010, **19**:1245–1257.
3. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF: **Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity.** *Anesthesiology* 2004, **101**:703–709.
4. Mandal PK, Fodale V: **Isoflurane and desflurane at clinically relevant concentrations induce amyloid beta-peptide oligomerization: an NMR study.** *Biochem Biophys Res Commun* 2009, **379**:716–720.
5. Mandal PK, Pettegrew JW, McKeag DW, Mandal R: **Alzheimer's disease: halothane induces A β peptide to oligomeric form—solution NMR studies.** *Neurochem Res* 2006, **31**:883–890.
6. Brasil LJ, San-Miguel B, Kretzmann NA, Amaral JL, Zettler CG, Marroni N, Gonzalez-Gallego J, Tunon MJ: **Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol.** *Toxicology* 2006, **227**:53–61.
7. Buzaleh AM, Garcia-Bravo M, Navarro S, Moran-Jimenez MJ, Mendez M, Batlle A, Fontanellas A, de Salamanca RE: **Volatile anaesthetics induce biochemical alterations in the heme pathway in a B-lymphocyte cell line established from hepatoerythropoietic porphyria patients (LBHEP) and in mice inoculated with LBHEP cells.** *Int J Biochem Cell Biol* 2004, **36**:216–222.
8. Kadioglu E, Sardas S, Erturk S, Ozatamer O, Karakaya AE: **Determination of DNA damage by alkaline halo and comet assay in patients under sevoflurane anesthesia.** *Toxicol Ind Health* 2009, **25**:205–212.
9. Karabiyik L, Sardas S, Polat U, Kocabaş NA, Karakaya AE: **Comparison of genotoxicity of sevoflurane and isoflurane in human lymphocytes studied in vivo using the comet assay.** *Mutat Res* 2001, **492**:99–107.
10. Loop T, Dovi-Akue D, Frick M, Roesslein M, Egger L, Humar M, Hoetzel A, Schmidt R, Borner C, Pahl HL, Geiger KK, Pannen BH: **Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro.** *Anesthesiology* 2005, **102**:1147–1157.
11. Matsuoka H, Kurosawa S, Horinouchi T, Kato M, Hashimoto Y: **Inhalation anesthetics induce apoptosis in normal peripheral lymphocytes in vitro.** *Anesthesiology* 2001, **95**:1467–1472.
12. Puig NR, Ferrero P, Bay ML, Hidalgo G, Valenti J, Amerio N, Elena G: **Effects of sevoflurane general anesthesia: immunological studies in mice.** *Int Immunopharmacol* 2002, **2**:95–104.
13. Yang H, Liang G, Hawkins BJ, Madesh M, Pierwola A, Wei H: **Inhalational anesthetics induce cell damage by disruption of intracellular calcium homeostasis with different potencies.** *Anesthesiology* 2008, **109**:243–250.
14. Horn NA, de RL, Robitzsch T, Hecker KE, Hutschenreuter G, Rossaint R: **The effects of sevoflurane and desflurane in vitro on platelet-leukocyte adhesion in whole blood.** *Anaesthesia* 2003, **58**:312–319.
15. Yuki K, Astrof NS, Bracken C, Soriano SG, Shimaoka M: **Sevoflurane binds and allosterically blocks integrin lymphocyte function-associated antigen-1.** *Anesthesiology* 2010, **113**:600–609.
16. Elena G, Amerio N, Ferrero P, Bay ML, Valenti J, Colucci D, Puig NR: **Effects of repetitive sevoflurane anaesthesia on immune response, select biochemical parameters and organ histology in mice.** *Lab Anim* 2003, **37**:193–203.
17. Kalimeris K, Christodoulaki K, Karakitsos P, Batistatou A, Lekka M, Bai M, Kitsioulis E, Nakos G, Kostopanagiotou G: **Influence of propofol and volatile anesthetics on the inflammatory response in the ventilated lung.** *Acta Anaesthesiol Scand* 2011, **55**:740–748.
18. Loop T, Scheiermann P, Doviakue D, Musshoff F, Humar M, Roesslein M, Hoetzel A, Schmidt R, Madea B, Geiger KK, Pahl HL, Pannen BH: **Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway.** *Anesthesiology* 2004, **101**:710–721.
19. Schneemilch CE, Hachenberg T, Ansoorge S, Ittenson A, Bank U: **Effects of different anaesthetic agents on immune cell function in vitro.** *Eur J Anaesthesiol* 2005, **22**:616–623.
20. Wada H, Seki S, Takahashi T, Kawarabayashi N, Higuchi H, Habu Y, Sugahara S, Kazama T: **Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance.** *Anesthesiology* 2007, **106**:499–506.
21. Roesslein M, Frick M, Auwaerter V, Humar M, Goebel U, Schwer C, Geiger KK, Pahl HL, Pannen BH, Loop T: **Sevoflurane-mediated activation of p38-mitogen-activated stresskinase is independent of apoptosis in Jurkat T-cells.** *Anesth Analg* 2008, **106**:1150–1160.
22. Biao Z, Zhanggang X, Hao J, Changhong M, Jing C: **The in vitro effect of desflurane preconditioning on endothelial adhesion molecules and mRNA expression.** *Anesth Analg* 2005, **100**:1007–1013.
23. Lee KH, Park JS, Lee SI, Kim JY, Kim KT, Choi WJ, Kim JW: **Anesthetic management of the emergency laparotomy for a patient with multiple sclerosis - a case report-.** *Korean J Anesthesiol* 2010, **59**:359–362.

24. Inoue S, Furuya H: Sevoflurane is safe for anesthetic management in patients with multiple sclerosis. *Acta Anaesthesiol Taiwan* 2006, **44**:187–189.
25. Yamashita K, Yokoyama T, Tokai H, Imazu Y, Lee M, Manabe M: Anesthetic management for a patient with multiple sclerosis at exacerbation stage under general anesthesia [in Japanese]. *Masui* 2003, **52**:521–523.
26. Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, Feinstein DL, Dello RC: Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. *J Neuroimmunol* 2012, **243**:43–51.
27. Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, Bongarzone ER, Feinstein DL: P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. *J Neuroinflammation* 2008, **5**:33.
28. Trojanowski JQ, Atkinson B, Lee VM: An immunocytochemical study of normal and abnormal human cerebrospinal fluid with monoclonal antibodies to glial fibrillary acidic protein. *Acta Cytol* 1986, **30**:235–239.
29. Matsuse S, Hara Y, Ohkura T, Yahagi N: Quantitative analysis of changes in blood concentrations and 'presumed effect-site concentration' of sevoflurane during one-lung ventilation. *Anaesthesia* 2012, **67**:1125–1131.
30. Zampieri FG, Park M, Machado FS, Azevedo LC: Sepsis-associated encephalopathy: not just delirium. *Clinics (Sao Paulo)* 2011, **66**:1825–1831.
31. Lamar CD, Hurley RA, Taber KH: Sepsis-associated encephalopathy: review of the neuropsychiatric manifestations and cognitive outcome. *J Neuropsychiatry Clin Neurosci* 2011, **23**:237–241.
32. Berg RM, Moller K, Bailey DM: Neuro-oxidative-nitrosative stress in sepsis. *J Cereb Blood Flow Metab* 2011, **31**:1532–1544.
33. Rappaport B, Mellon RD, Simone A, Woodcock J: Defining safe use of anesthesia in children. *N Engl J Med* 2011, **364**:1387–1390.
34. Hudson AE, Hemmings HC Jr: Are anaesthetics toxic to the brain? *Br J Anaesth* 2011, **107**:30–37.

doi:10.1186/1742-2094-9-272

Cite this article as: Polak et al.: Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis. *Journal of Neuroinflammation* 2012, **9**:272.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

